NanoLogix Files Six Additional Patent Applications That Enhance its Hydrogen Bioreactor Technologies Sep 12, 2006 11:25:00 AM SHARON, Pa., Sept. 12 /PRNewswire-FirstCall/ -- NanoLogix, Inc. (OTC: NNLX), a nano-biotechnology company engaged in the research, development and commercialization of technologies for alternative sources of fuel, today announced that it has filed six additional patent applications that enhance the production of hydrogen utilizing its proprietary hydrogen bioreactor. Including today's announcement, the Company has filed a total of 22 patent applications related to its hydrogen bioreactor.
Earlier this year, President Bush issued the Advanced Energy Initiative, allocating millions of dollars to help decrease the nation's dependence on foreign sources of energy, as well as accelerate the adoption of more affordable, alternative sources of energy throughout the year 2015. Since 2001, the U.S. has spent nearly $10 billion on the development of alternative energy sources. The Advanced Energy Initiative provides for a 22% increase in clean-energy research at the Department of Energy (DOE). NanoLogix' hydrogen bioreactor technology platform provides an alternative energy source that meets the objectives of the DOE's call to action to create cleaner, more affordable and reliable sources of energy in the U.S.
David F. Rivers, a director of NanoLogix and CEO of Patriot Lift Company (http://www.patriotlift.com), who previously spent more than 30 years with Pfizer's Schick & Wilkinson Sword business unit and General Motors' Fisher Body Division in Senior Research, Development and Engineering Operations, commented, "We know our reliance on fossil fuels has created an energy crisis of global proportions. Ground sources are rapidly dwindling, and researchers have concluded the world is consuming oil more than two times faster than the rate of new discovery. Through our hydrogen bioreactor technologies and patent-pending processes, we can demonstrate the viability of clean-burning, cost-effective hydrogen as a source of alternative energy. The evolution of hydrogen as a fuel source is on an accelerated path for growth, and we believe NanoLogix can play an active role in its commercialization."
About NanoLogix, Inc.
NanoLogix is an industry innovator in the research, development and commercialization of nano-biotechnologies, applications and processes. The Company owns or has the rights to 32 patented technologies. The Company is currently focused on the production of hydrogen from agricultural feedstock, industrial wastewater and municipal waste streams to create new sources of energy. NanoLogix is presently operating a hydrogen bioreactor at Welch's Food and has recently signed an agreement with the City of Erie Wastewater Treatment Plant for a prototype bioreactor installation. Additionally, NanoLogix develops and markets diagnostic test kits for use in early detection of infectious human diseases such as cancer, cystic fibrosis and AIDS, and owns a patent for the non-toxic induction of apoptosis ("cell suicide") for the treatment of cancer. For more information on the Company, visit http://www.nanologix.net.
This press release contains statements, which may constitute "forward- looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of NanoLogix, Inc., and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.
SOURCE NanoLogix, Inc.
---------------------------------------------- Peter Clark Investor Relations of OTC Financial Network +1-781-444-6100 x625 or peter@otcfn.com
News 
Market Data 
Discover 
AI
